Aventis Pharma S.a.

Sanofi

Sanofi-a Ventis Deutschland Gmbh

Cecile Combeau

Karl Schoenafinger

Hans Matter

Jean-Christophe Carry

David William Will

Laurent Schio

Gunter Muller

Francois Clerc

Anke Steinmetz

Swen Hoelder

Ingrid Sassoon

Christine Delaisi

Martin Bossart

Michel Cheve

Didier Benard

Alain Krick

Sylvette Lachaud

Sylvie Gontier

Serge Mignani

Bruno Filoche-Romme

Jacques Mauger

Anil Nair

Hervé Minoux

Kirsten Bjergarde

Odile Angouillant-Boniface

Nina Ma

The invention relates to a compound of formula (I), more specifically in the levorotatory form (1a) thereof, in particular the form having a rotatory power [&#x3b1;]D=&#x2212;38.6+0.7 at a concentration of 0.698 mg/ml in methanol. The compound may be in the form of a base or an acid addition salt, in particular a pharmaceutically acceptable acid. The compound is a selective Aurora A and B kinase inhibitor and can be used as an anticancer drug.

Anti-cancer compound and pharmaceutical composition containing the same

The invention relates to a compound of formula (I), more specifically in the levorotatory form (1a) thereof, in particular the form having a rotatory power [&#x3b1;]D=&#x2212;38.6+0.7 at a concentration of 0.698 mg/ml in methanol. The compound may be in the form of a base or an acid addition salt, in particular a pharmaceutically acceptable acid. The compound is a selective Aurora A and B kinase inhibitor and can be used as an anticancer drug. 

This invention relates to compounds of formula (I) to processes for the preparation of such compounds, to pharmaceutical compositions comprising such compounds, and to methods of treatment comprising administering of such compounds.

1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them

Disclosed are compounds of Formula I wherein X is and R, R, A, B, D, E, Rare as defined herein useful for treating cancers.

Pyridazinone kinase inhibitors

Disclosed are compounds of the general formula (I), where the definition of the substituents A, B, D, E, Rand Rare detailed in the description, and the physiologically tolerated salts thereof, a process for the preparation of these compounds and their use as pharmaceuticals.  These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).

4-benzimidazol-2-ylpyridazin-3-one derivatives

Disclosed are compounds according to the general formula (I), where the definitions of the substituents X, Rand Rare detailed in the description, as well as their physiologically acceptable salts and solvate, methods for producing these compounds and their use as pharmaceuticals.  These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).

Pyridazinone derivatives

Growing community of inventors

Fontenay aux Roses, France

Cecile Combeau